Skip to main content
PM Immunity Nebeling
© DZNE/Felix Nebeling

News categories: Publication

Study reveals dynamic interactions between brain tumors and immune cells

Glioblastoma, the most common and aggressive brain tumor in adults, is difficult to treat because this cancer can invade the surrounding brain tissue and spread far beyond the original tumor mass. Researchers from the DZNE, the University Hospital Bonn (UKB), and ImmunoSensation³ at the University of Bonn have observed this infiltration process in the living brain using high-tech microscopy. Their study is based on research in mice with a form of brain tumor that closely resembles human glioblastoma.

The findings, published in the journal *Immunity*, reveal complex and context-dependent interactions between glioblastoma cells and the brain’s immune cells, known as microglia. These cells patrol the tissue in search of threats. The findings suggest that they are not merely passive observers, but actively influence both the containment and spread of the tumor.

The researchers captured these processes using “three-photon microscopy,” which utilizes infrared light. They focused on the “distant infiltration zone.” This area of tissue is located several millimeters away from the primary tumor.

Changing Behavior

Among other things, the team found that the behavior of microglia changed as the tumor spread. When only a few tumor cells were present, the microglia were particularly mobile and highly active in their “surveillance function”—that is, in scanning the brain. However, as infiltration increased, this immune response waned. The researchers also investigated the consequences of deactivating a specific surface receptor through which microglia perceive their environment. Furthermore, they analyzed how a drastic reduction in immune cells affected tumor spread.

“Our data show that interactions between tumor cells and microglia play an important role in the spread of glioblastoma,” says Dr. Felix Nebeling, first author of the study. “Targeting the microglia - for example, with drugs - could therefore be a promising approach to limiting tumor spread and improving treatment outcomes.”

Funding

The study involved the DZNE, the UKB, the University of Bonn, the University Medical Center Mannheim, and University College London.

Publication

Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone, Felix Nebeling et al., Immunity (2026), DOI: https://doi.org/10.1016/j.immuni.2026.03.010

Contact

Felix Nebeling
Klinik für Neuroonkologie am UKB
DZNE
E-Mail: felix.nebeling@ukbonn.de

 

Related news

Bunte Spirale

News categories: Publication

When the map needs an update

Every time we move through a familiar environment, the hippocampus consults an internal map, a detailed spatial representation that is built up through repeated experience. But what happens when something unexpected occurs on a well-known route? Researchers at the UKB and the University of Bonn were able to demonstrate in a mouse model that the brain does not redraw its maps from scratch. Instead, it annotates them: preserving the underlying spatial layout while overlaying new information on top of the existing map. Their findings have now been published in the journal PNAS.
View entry
Dr. Clivia Lisowski und Prof. Christian Kurts

News categories: Publication

Immune cells in the liver help pigeons navigate

How do pigeons find their way home safely over distances of many kilometers? A research team from the University Hospital Bonn (UKB), the University of Bonn, the University of Duisburg-Essen, and the Max Planck Institute for Behavioral Biology has now discovered a previously unknown mechanism: specific immune cells in the liver may help the birds detect the Earth’s magnetic field. The findings have now been published in the journal Science.
View entry
News Icon

News categories: Publication

Twin Lancet Publications Highlight Promising New Approach for Lupus Treatment

A team of international researchers, including ImmunoSensation³ member Prof. Jörg Wenzel, reports promising phase 2 results for enpatoran, a first-in-class oral TLR7/8 inhibitor, in patients with cutaneous and systemic lupus erythematosus (CLE/SLE). In the WILLOW trial, enpatoran significantly improved skin disease activity in a dose-dependent manner and showed favourable safety outcomes. In systemic SLE, treatment also reduced global disease activity and rapidly suppressed the type I interferon gene signature. The twin studies were published in The Lancet and The Lancet Rheumatology.
View entry

Back to the news overview